These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31171642)

  • 41. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.
    Soulika AM; Khan MM; Hattori T; Bowen FW; Richardson BA; Hack CE; Sahu A; Edmunds LH; Lambris JD
    Clin Immunol; 2000 Sep; 96(3):212-21. PubMed ID: 10964539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition.
    Janssen BJ; Halff EF; Lambris JD; Gros P
    J Biol Chem; 2007 Oct; 282(40):29241-7. PubMed ID: 17684013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence suggesting the occurrence of C3-independent intravascular immune hemolysis. Reactive hemolysis in vivo.
    Salama A; Bhakdi S; Mueller-Eckhardt C
    Transfusion; 1987; 27(1):49-53. PubMed ID: 3810824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells.
    Salama A; Mueller-Eckhardt C
    Transfusion; 1984; 24(3):188-93. PubMed ID: 6610232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3.
    Sahu A; Morikis D; Lambris JD
    Mol Immunol; 2003 Jan; 39(10):557-66. PubMed ID: 12431389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
    Hajishengallis G; Kajikawa T; Hajishengallis E; Maekawa T; Reis ES; Mastellos DC; Yancopoulou D; Hasturk H; Lambris JD
    Front Immunol; 2019; 10():406. PubMed ID: 30915073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.
    Tamamis P; Morikis D; Floudas CA; Archontis G
    Proteins; 2010 Sep; 78(12):2655-67. PubMed ID: 20589629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Studies of structure-activity relations of complement inhibitor compstatin.
    Soulika AM; Morikis D; Sarrias MR; Roy M; Spruce LA; Sahu A; Lambris JD
    J Immunol; 2003 Aug; 171(4):1881-90. PubMed ID: 12902490
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solution structure of Compstatin, a potent complement inhibitor.
    Morikis D; Assa-Munt N; Sahu A; Lambris JD
    Protein Sci; 1998 Mar; 7(3):619-27. PubMed ID: 9541394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
    Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
    Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.
    Merle NS; Grunenwald A; Rajaratnam H; Gnemmi V; Frimat M; Figueres ML; Knockaert S; Bouzekri S; Charue D; Noe R; Robe-Rybkine T; Le-Hoang M; Brinkman N; Gentinetta T; Edler M; Petrillo S; Tolosano E; Miescher S; Le Jeune S; Houillier P; Chauvet S; Rabant M; Dimitrov JD; Fremeaux-Bacchi V; Blanc-Brude OP; Roumenina LT
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunological damage to erythrocytes].
    Engelfriet CP; von dem Borne AE; Fleer A; van der Meulen FW; Beckers D; van Treslong JP; Matthijse-Dekker A; Linthout-Goorhuis E
    Schweiz Med Wochenschr; 1976 Oct; 106(40):1330-6. PubMed ID: 1006250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
    Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
    Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.
    Maekawa T; Briones RA; Resuello RR; Tuplano JV; Hajishengallis E; Kajikawa T; Koutsogiannaki S; Garcia CA; Ricklin D; Lambris JD; Hajishengallis G
    J Clin Periodontol; 2016 Mar; 43(3):238-49. PubMed ID: 26728318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 60. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.